Epiminder, a company developing breakthrough epilepsy monitoring tech, announced the first implant of the Minder system in the U.S.

The Perelman School of Medicine at the University of Pennsylvania, the first site to join the Diagnosing Epilepsy To Effect Change (DETECT) study, enrolled and implanted the first study patient. The company also revealed four other sites have enrolled in the study and are recruiting patients, including the Mayo Clinic Rochester, Mayo Clinic Jacksonville and Mayo Clinic Phoenix, and Beth Israel Deaconess Medical Center.

The DETECT study is the first RCT to compare patients implanted with Minder to standard of care monitoring to spot clinically actionable events in patients with drug-resistant epilepsy. In the six-month study, 201 subjects with receive the implant at up to 25 U.S. sites.

The study’s goal is to show that continuous EEG monitoring is superior to standard of care to identify clinically actionable events in patients with drug-resistant epilepsy.

“I am thrilled to be able to offer this innovative technology as we implant our first patient in the DETECT study,” said The Perelman School of Medicine at the University of Pennsylvania’s Assistant Professor of Clinical Neurology, Dr. Taneeta Mindy Ganguly, who specializes in epilepsy. “Standard EEG methods do not offer the long-term EEG monitoring necessary to make informed management decisions for many of our patients. The ability to provide continuous, high-fidelity monitoring over months and years bridges that critical diagnostic gap with far reaching implications for patients and providers. The long-term EEG data obtained is key in unlocking the future of epilepsy care, allowing us to achieving better outcomes and quality of life for our patients.”

“This first US implant of our Minder device marks a watershed moment for Epiminder and the global epilepsy community,” added Rohan Hoare, CEO of Epiminder. “We are excited to take the next step in translating years of rigorous scientific development and clinical validation into real-world impact for patients who have exhausted traditional monitoring options. Dr. Ganguly and her team at Penn Medicine represent the exceptional clinicians who will help us begin to unlock Minder’s full potential. Their expertise and dedication to advancing drug-resistant epilepsy care embody exactly why we built this device. Consistent with our commercialization strategy, with each patient enrolled in DETECT, we move closer to our mission: empowering clinicians with objective, continuous brain activity data and ultimately providing the 52 million people living with epilepsy worldwide with the answers, insights, and hope they deserve. This study is just the beginning of what we believe will be a fundamental transformation in how the world diagnoses and manages epilepsy.”

In July 2025, the company touted published results from its landmark UMPIRE (sUb-scalp Monitoring ePileptic seIzuREs) clinical trial that validate the safety and efficacy of its implantable continuous EEG monitoring (iCEM) technology.